1-7 of 7
Angelika Bischof Delaloye
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Anton Hagenbeek, MD, PhD, John Radford, MD, Achiel Van Hoof, MD, Umberto Vitolo, MD, Ama Z.S. Rohatiner, MD, Gilles Salles, MD, PhD, Pierre Soubeyran, MD, PhD, Herve Tilly, MD, Angelika Bischof Delaloye, MD, Wim L.J. van Putten, MSc, Franck Morschhauser, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 594.
https://doi.org/10.1182/blood.V116.21.594.594
Published: 2010
Journal Articles

Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network.

Wojciech Jurczak, MD, Aleksander B. Skotnicki, MD, Andrzej Deptala, MD, Christine Windemuth-Kieselbach, PhD, Michael Lorsbach, Angelika Bischof Delaloye, MD, Suh Cheolwon, MD, Pier Luigi Zinzani, MD, Roberto Cacchione, MD, Werner Linkesch, MD, Francesco d'Amore, MD, Lorenz H. Truemper, MD
Journal: Blood
Blood (2009) 114 (22): 3746.
https://doi.org/10.1182/blood.V114.22.3746.3746
Published: 2009
Journal Articles

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z S Rohatiner, MD, Gilles Andre Salles, MD, PhD, Jens Kuhlmann, Willem JL Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek
Journal: Blood
Blood (2008) 112 (11): 2002.
https://doi.org/10.1182/blood.V112.11.2002.2002
Published: 2008
Journal Articles

Efficacy of Yttrium-90 Zevalin Outside of Clinical Trials: Preliminary Results of a Retrospective Bi-Center Study

Francesco Cicone, Francesco Scopinaro, Sebastien Baechler, Nicolas Ketterer, Franz Buchegger, M. Christina Cox, Gilles Allenbach, Anna Tofani, Angelika Bischof Delaloye
Journal: Blood
Blood (2008) 112 (11): 5015.
https://doi.org/10.1182/blood.V112.11.5015.5015
Published: 2008
Journal Articles

Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90 Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT).

Kathleen Gondek, Sonalee Shah, Angelika Bischof-Delaloye, Ama Rohatiner, Gilles Salles, Barbara Putz, Michael Kunz, Anton Hagenbeek
Journal: Blood
Blood (2007) 110 (11): 3319.
https://doi.org/10.1182/blood.V110.11.3319.3319
Published: 2007
Journal Articles

Dosimetric Analysis of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Given as Consolidation of First Remission in Patients with Advanced-Stage Follicular Lymphoma in the International Phase 3 First-Line Indolent Trial (FIT).

Angelika Bischof-Delaloye, Cristian Antonescu, Anton Hagenbeek
Journal: Blood
Blood (2007) 110 (11): 3415.
https://doi.org/10.1182/blood.V110.11.3415.3415
Published: 2007
Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.

Anton Hagenbeek, Angelika Bischof-Delaloye, John A. Radford, Ama Rohatiner, Gilles Salles, Achiel Van Hoof, Barbara Putz, Michael Kunz, Franck Morschhauser
Journal: Blood
Blood (2007) 110 (11): 643.
https://doi.org/10.1182/blood.V110.11.643.643
Published: 2007